Differential effect of adalumimab versus etanercept on apoptosis in the psoriatic skin

Differential effect of adalumimab versus etanercept on apoptosis in the psoriatic skin - Adalumimab versus etanercept; apoptosis in the psoriatic skin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30655

Enrollment

Registered

2007-05-02

Start date

2007-05-02

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis psoriatica

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Man and woman older than 18 year en younger than 75 year 2. Diagnosis of Psoriatic arthritis with involvement of the peripheral joints 3. Failure on etanercept therapy as measured by PASI and DAS 4. Indication for treatment with etanercept according to the LABAG guidelines 5. Active disease despite treatment with methotrexate and etanercept, MTX >_ 15 mg/wk in a stable dosis during 3 months; still active skin lesions despite MTX and etanercept treatment 5. Corticosteroids (max 10 mg/day) en NSAID*s stable dose. 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Rheumatoid arthritis and/or other autoimmune diseases 2. Pregnancy / breastfeeding. 3. TBC/ hepatitis b or c or other chronic infections. 4. Contraindications for TNF-alpha like a malignancy or a chronic demyelinating disease. 5. No participation in another study. 6. No PUVA or vitamine D treatment during 1 month before and during the study.

Design outcomes

Primary

Measure	Time frame
Primary 1. Amount of apoptotic cells 2. Evaluation of cellular infiltrates	—

Secondary

Measure	Time frame
Secondary 1. Clinical improvement; DAS response criteria, PASI skin score.	—

Countries

Netherlands

Outcome results